Roman S. Erdmann
Head of Bioconjugation @Mersana Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
Head of Bioconjugation @Mersana Therapeutics
Cambridge, MA, US
Lead and manage a high-performing team of 6 researchers (2 Principal Scientists, 2 Scientists, 1 Senior Principal Associate Scientist, 1 Senior Associate Scientist), fostering a culture of engagement and insuring individual career development.• Initiate, nurture, and drive the science aimed at the discovery of new bioconjugation technologies, platforms, and ADC approaches. Develop a strategic vision for these activities aligning with Mersana’s long-term objectives over the next 1-2 years.• Actively influence molecular mechanism of action studies related to established platforms and providing expert guidance and mentorship to five discovery candidate seeking project teams.• Design and implement a highly efficient ADC request and tracker system, streamlining coordination and enhancing transparency regarding available bioconjugation resources within the team and across collaborating departments to ensure the timely delivery of our commitments.• Collaborate seamlessly with cross-functional teams including Discovery Chemistry, Discovery Analytical, Biology and CMC to advance strategic projects, initiatives, and scientific endeavors, fostering a synergistic approach to achieving shared goals.
EDUCATION
University of Basel
Doctor of Philosophy - PhD, Chemistry
University of Basel
Bachelor of Science - BS, Chemistry
ETH Zürich
Doctor of Philosophy - PhD, Chemistry
Yale University
Postdoc, Chemical Biology and Cell Biology
University of Basel
Master of Science - MS, Chemistry
ABOUT ROMAN S. ERDMANN
Accomplished Chemical Biologist with over a decade of interdisciplinary postgraduate experience, excelling in diverse fields such as organic chemistry, pharmacology, cell and molecular biology. Recognized for contributions to the scientific community through 20 peer-reviewed publications, a granted patent, and 4 filed patent applications.• Proficient in a wide range of modalities, including small molecules, peptides, induced proximity (e.g. targeted protein degradation), lipid nanoparticles/mRNA, and ADCs. • Specialized in the design and implementation of cell-based target identification and validation platforms, as well as various cell-based assays. Demonstrated expertise in identifying binding sites and conducting target engagement studies. Skilled in leveraging (chemo)proteomics and super-resolution imaging techniques across multiple disease areas.• Dynamic leader with a passion for teaching and mentoring multidisciplinary teams, adept at effectively communicating with chemists, biologists, and pharmacologists to foster collaborative environments and drive innovation.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.